What is the official website of NordicInfu Care AB ?

The official website of NordicInfu Care AB is http://www.infucare.com.

What is NordicInfu Care AB's cybersecurity risk score?

NordicInfu Care AB has an AI-generated cybersecurity risk score of 753 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has NordicInfu Care AB experienced?

According to Rankiteo, NordicInfu Care AB currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has NordicInfu Care AB been affected by any supply chain cyber incidents ?

According to Rankiteo, NordicInfu Care AB has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does NordicInfu Care AB have SOC 2 Type 1 certification ?

According to Rankiteo, NordicInfu Care AB is not certified under SOC 2 Type 1.

Does NordicInfu Care AB have SOC 2 Type 2 certification ?

According to Rankiteo, NordicInfu Care AB does not hold a SOC 2 Type 2 certification.

Does NordicInfu Care AB comply with GDPR ?

According to Rankiteo, NordicInfu Care AB is not listed as GDPR compliant.

Does NordicInfu Care AB have PCI DSS certification ?

According to Rankiteo, NordicInfu Care AB does not currently maintain PCI DSS compliance.

Does NordicInfu Care AB comply with HIPAA ?

According to Rankiteo, NordicInfu Care AB is not compliant with HIPAA regulations.

Does NordicInfu Care AB have ISO 27001 certification ?

According to Rankiteo,NordicInfu Care AB is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does NordicInfu Care AB operate in ?

NordicInfu Care AB operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does NordicInfu Care AB have ?

NordicInfu Care AB employs approximately 136 people worldwide.

Does NordicInfu Care AB own any subsidiaries ?

NordicInfu Care AB presently has no subsidiaries across any sectors.

How many LinkedIn followers does NordicInfu Care AB have ?

NordicInfu Care AB's official LinkedIn profile has approximately 3,090 followers.

What is the NAICS classification code for NordicInfu Care AB ?

NordicInfu Care AB is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does NordicInfu Care AB have a Crunchbase profile ?

No, NordicInfu Care AB does not have a profile on Crunchbase.

Does NordicInfu Care AB have a LinkedIn profile ?

Yes, NordicInfu Care AB maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/nordicinfu-care-ab.

How many cybersecurity incidents has NordicInfu Care AB experienced ?

As of July 19, 2026, Rankiteo reports that NordicInfu Care AB has not experienced any cybersecurity incidents.

How many peer or competitor companies does NordicInfu Care AB have ?

NordicInfu Care AB has an estimated 5,710 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

NCA

Boost Score +25 with badge (5 left)

753

/1000

Fair

778

/1000

Fair

NordicInfu Care AB Vendor Cyber Rating & Cyber Score

infucare.com

Add Your Compliance Badge

Nordic Infucare started its journey as an entrepreneurial company with the desire to do things differently. Mats Bergryd founded the business to offer specialized treatments in a home environment, serving patients who suffer from chronic disease. He chose that niche as he, after 20 years in the industry, had identified a gap between what was possible to achieve with smart technology and pharmaceuticals, and the actual results. Mats concluded that there was an opportunity to increase the quality of life for patients with chronic disease by closing the gap, and that it would be good business for the one who succeeded. Since the start in 2004 we have grown into a company with more than 100 employees. Today we are a part of the Air Liquide

NCA A.I CyberSecurity Scoring

Scoring History

NCA

NordicInfu Care AB CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

NCA Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for NCA

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for NordicInfu Care AB in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for NordicInfu Care AB in 2026.

Incident Types NCA vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for NordicInfu Care AB in 2026.

Incident History - NCA (X = Date, Y = Severity)

Loading…

SUBSIDIARY

NordicInfu Care AB Subsidiaries

NCA

Pharmaceutical Manufacturing

Website: http://www.infucare.com

Company Size: 136

Air Liquide HealthcareHealth and Human Services

SEPPICChemical Manufacturing

Air LiquideChemical Manufacturing

AirgasChemical Manufacturing

Air Liquide Engineering & TechnologiesChemical Manufacturing

ALIAD (Air Liquide Venture Capital)Venture Capital and Private Equity Principals

ALIZENTIT Services and IT Consulting

CARBAGAS AG / Air LiquideChemical Manufacturing

ACCELAIR Strategic Management Services

VitalAireHospitals and Health Care

ORKYN'Home Health Care Services

Air Liquide Medical SystemsMedical Device

Dinno santéHome Health Care Services

Medicasa ItaliaHospitals and Health Care

BioKryoBiotechnology Research

Gasoxmed - Gases Medicinais S.A.Home Health Care Services

Air Liquide Healthcare AustraliaHospitals and Health Care

VitalAire Diabetes South AfricaMedical Equipment Manufacturing

Loading…

NordicInfu Care AB Similar Companies

MANKIND PHARMA LTD

mankindpharma.com

Mankind Pharma, one of the top 5 leading pharmaceutical companies in India, started its journey in 1995. Today, we have an employee base of over 20,000 and are racing towards $1 Billion. At Mankind, we aspire to aid the community in leading a healthy life by formulating, developing, commercializing, and delivering affordable and accessible medicines that satisfy urgent medical needs. We take great pride in the success of our products ranging from Pharma, OTC and FMCG brands like Manforce Condoms, Manforce Tablets, Manforce Staylong Gel, Unwanted 72, Prega News, Gas-O-Fast, Kaloree 1, Kabzend, Acne Star Gel and many others. Our operations are in 34 overseas destinations across Asia, Africa, South-East Asia, Gulf countries and CIS countries. Our Vision - To be a global pharmaceutical company, most admired for its Affordability, Quality and Accessibility of products. Our Mission - To be able to provide cost-effective, innovation based superior quality pharmaceutical products across the globe, to improve the lives of the patients. Mankind strongly believes and follows its Core Values: 𝐂𝐮𝐬𝐭𝐨𝐦𝐞𝐫 𝐂𝐞𝐧𝐭𝐫𝐢𝐜𝐢𝐭𝐲: Commitment to Customer - Internal and External 𝐐𝐮𝐚𝐥𝐢𝐭𝐲: It is in our DNA to maintain and deliver highest quality standards and products 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: Intensely Research driven organization aiming at product innovation and technology improvements 𝐈𝐧𝐭𝐞𝐠𝐫𝐢𝐭𝐲: Always trustworthy, widely respected to be honest, and believed by everyone 𝐆𝐨 𝐁𝐞𝐲𝐨𝐧𝐝: Aim higher than capabilities 𝐏𝐞𝐨𝐩𝐥𝐞 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧: Together we are foreseeing future and diligently stimulating our people in attaining goals

Glenmark Pharmaceuticals

glenmarkpharma.com

Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the past four and a half decades, we have evolved from a generics company to a global organization offering specialty and branded products. Glenmark’s core values of Achievement, Respect, and Knowledge impart a sense of organizational unity that drives our growth. We have established a robust global branded generics, specialty, and OTC business; with a significant presence in the therapy areas of dermatology, respiratory, and oncology. Our ten state-of-the-art manufacturing facilities spread across four continents with operations in over 80 countries help us impact millions of patients across the globe. We recently consolidated our innovation efforts in small molecules and biologics research with the formation of ‘Ichnos Glenmark Innovation’ (IGI). This alliance is aimed at leveraging the capabilities of Glenmark and its subsidiary, Ichnos Sciences, to accelerate innovation in cancer treatment. To know more about IGI, check out: https://iginnovate.com/ Sustainability is an integral aspect of all our operations and we are focused on achieving our Environment, Social and Governance (ESG) goals. Our responsibility also extends to our communities, and over the years, our CSR efforts have touched the lives of over 3 million people.

MENARINI Group

menarini.com

The Menarini Group is a leading international pharmaceutical and diagnostics company, present in 140 countries worldwide, with a turnover of 4,37 Billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants, which produce over 609 million packets of product a year and distribute them to five continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group

Sanofi

sanofi.com

We are an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms

AUROBINDO PHARMA LTD

aurobindo.com

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, branded specialty drugs, and active pharmaceutical ingredients (APIs) across more than 150 countries. It is ranked among the top 10 generic companies in eight European nations and holds the distinction of being the largest generic pharmaceutical company in the United States. With over 30 state-of-the-art manufacturing and packaging facilities approved by leading global regulatory authorities including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA, Aurobindo Pharma ensures the highest standards of quality. Its robust portfolio spans eight major therapeutic areas: Central Nervous System (CNS), Antiretroviral (ARV), Cardiovascular (CVS), Antibiotics, Gastroenterology, Anti-diabetics, Oncology, and Dermatology, supported by a strong R&D infrastructure that drives innovation, affordability, and accessibility.

Torrent Pharmaceuticals Ltd

cb torrentpharma.com

Torrent Pharma, with annual revenues of more than Rs 10,700 crores, is the flagship Company of the Torrent Group, with group revenues of Rs 41,000 crores. It is ranked 5th in the Indian Pharma Market and is among the Top 5 in the therapeutic segments of Cardiovascular (CV), Central Nervous System (CNS), Gastro-intestinal (GI), Vitamins Minerals Nutritionals (VMN) and Cosmo-Dermatology. The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent has 8 manufacturing facilities , of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing around 800 scientists. The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceuticals business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, Women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market. Torrent Pharma started international acquisitions in 2005 with entry into the German market. Today, the Company has presence in more than 50 countries and is ranked No. 1 among the Indian pharma Companies in Brazil and Germany. Torrent Pharma is committed towards “not just healthcare but lifecare.”

Lonza

lonza.com

Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.

Novo Nordisk

cb novonordisk.com

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 68,800 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

MSD

msd.com

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.com and connect with us on Facebook, Instagram, Twitter, and YouTube.

Loading…

NEWS

NordicInfu Care AB CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-16197

SUMMARY

A security vulnerability has been detected in Sipeed PicoClaw up to 0.2.9. The affected element is the function handleMessageReceive of the file pkg/channels/feishu/feishu_64.go of the component Group Message Handler. Such manipulation leads to missing authorization. The attack can be launched remotely. The exploit has been disclosed publicly and may be used. The reported GitHub issue was closed automatically due to inactivity.

Published

Date2026-07-18

Updated

Date2026-07-18

RISK INFORMATION (Score: 6.3)

cvss2

Base Score: 6.5

Complexity: LOW

AV:N/AC:L/Au:S/C:P/I:P/A:P

cvss3

Base Score: 6.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 2.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

2.8

REFERENCES

CVE-2026-16196

SUMMARY

A weakness has been identified in Sipeed PicoClaw up to 0.2.9. Impacted is the function isPrivateOrRestrictedIP of the file pkg/tools/integration/web.go of the component web_fetch. This manipulation causes server-side request forgery. The attack can be initiated remotely. The exploit has been made available to the public and could be used for attacks. Patch name: 2efbe5d560e7ed9bc5209c203dc4aa6ecdbc7405. To fix this issue, it is recommended to deploy a patch.

Published

Date2026-07-18

Updated

Date2026-07-18

RISK INFORMATION (Score: 6.3)

cvss2

Base Score: 6.5

Complexity: LOW

AV:N/AC:L/Au:S/C:P/I:P/A:P

cvss3

Base Score: 6.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 2.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

2.8

REFERENCES

CVE-2026-16195

SUMMARY

A security flaw has been discovered in Sipeed PicoClaw up to 0.2.9. This issue affects the function dispatchIncoming of the file pkg/channels/wecom/wecom.go of the component Group Message Handler. The manipulation results in incorrect authorization. It is possible to launch the attack remotely. The exploit has been released to the public and may be used for attacks. The reported GitHub issue was closed automatically due to inactivity.

Published

Date2026-07-18

Updated

Date2026-07-18

RISK INFORMATION (Score: 6.3)

cvss2

Base Score: 6.5

Complexity: LOW

AV:N/AC:L/Au:S/C:P/I:P/A:P

cvss3

Base Score: 6.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 2.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

2.8

REFERENCES

CVE-2026-10130

SUMMARY

QueryWeaver contains an authentication bypass vulnerability that allows unauthenticated attackers to obtain valid session tokens for existing accounts by submitting a signup request with a known victim email address. The signup route unconditionally creates and links a new token to the matching Identity via a Cypher MERGE operation before checking whether the email belongs to an existing account, causing the server to return a valid authenticated session token for the victim's identity without requiring any prior credentials or user interaction.

Published

Date2026-07-18

Updated

Date2026-07-18

RISK INFORMATION (Score: 8.2)

cvss3

Base Score: 8.2

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:L/A:N

cvss4

Base Score: 8.8

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:L/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

4.2

Exploitability

3.9

REFERENCES

CVE-2026-16194

SUMMARY

A vulnerability was determined in zhayujie CowAgent up to 2.1.1. This affects the function WebFetch.execute of the file agent/tools/web_fetch/web_fetch.py. Executing a manipulation of the argument url can lead to server-side request forgery. The attack may be performed from remote. The exploit has been publicly disclosed and may be utilized. Upgrading to version 2.1.2 is able to mitigate this issue. This patch is called ea47f3097eed4f8295c4cb3d76ecb97e0f43d632. It is recommended to upgrade the affected component. The vendor was contacted early, responded in a very professional manner and quickly released a fixed version of the affected product.

Published

Date2026-07-18

Updated

Date2026-07-18

RISK INFORMATION (Score: 6.3)

cvss2

Base Score: 6.5

Complexity: LOW

AV:N/AC:L/Au:S/C:P/I:P/A:P

cvss3

Base Score: 6.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 2.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

2.8

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…